Primary Sclerosing Cholangitis Market Insights, Share, Size, Trends, and Forecast 2032

June 15 01:49 2022
Primary Sclerosing Cholangitis Market Insights, Share, Size, Trends, and Forecast 2032

DelveInsight’s “Primary Sclerosing Cholangitis Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Primary Sclerosing Cholangitis (PSC), historical and forecasted epidemiology as well as the Primary Sclerosing Cholangitis (PSC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Primary Sclerosing Cholangitis (PSC) market report provides current treatment practices, emerging drugs, Primary Sclerosing Cholangitis (PSC) market share of the individual therapies, current and forecasted Primary Sclerosing Cholangitis (PSC) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Primary Sclerosing Cholangitis (PSC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Primary Sclerosing Cholangitis (PSC) market.


Primary Sclerosing Cholangitis: An Overview

Primary sclerosing cholangitis (PSC) is a rare cholestatic disorder of the liver, with strictures in the bile ducts leading to cirrhosis of the liver in a proportion of patients. The etiology of PSC is unknown; thus, PSC is generally considered as an idiopathic disease. PSC is commonly associated with inflammatory bowel disease and increased risk of cholangiocarcinoma, gall bladder cancer, colorectal cancer, and hepatocellular carcinoma. Medical therapies are primarily aimed at symptom management and disease-modifying therapies are limited. Endoscopic therapies are used in patients with dominant strictures and liver transplantation is a last resort.


Download a sample copy of the PSC Market Report-


Some of the key highlights of the Primary Sclerosing Cholangitis Market Report

  • Primary sclerosing cholangitis (PSC) is a rare progressive disorder characterized by inflammation, thickening, and abnormal formation of fibrous tissue (fibrosis) within the passages that carry bile from the liver (bile ducts). Both the bile ducts within the liver (intrahepatic) and outside the liver (extra hepatic) are affected.
  • PSC is a rare disease with a poor prognosis and can lead to cirrhosis of the liver or bile duct cancer. It affects 0.01% of the population but, even though it is rare, PSC is responsible for more than 10% of all liver transplants, making it the third commonest indication for liver transplant in Europe.
  • According to Gochanour et al., 2020, males are affected more as compared to females in case of Primary Sclerosing Cholangitis.


Primary Sclerosing Cholangitis Epidemiology Segmentation in the 7MM

  • Prevalent Cases
  • Prevalence
  • Comorbidities Associated


Primary Sclerosing Cholangitis Treatment Market

Treatments for PSC focus on managing complications and monitoring liver damage. Treatment for PSC includes medication to reduce itching and jaundice, antibiotics to treat infections and vitamin supplements since people with PSC are often deficient in vitamins A, D and K. In some cases, surgery to open major blockages in the common bile duct also is necessary. In addition, liver transplantation may be required and in some cases, can cure PSC.


Primary Sclerosing Cholangitis Pathogenesis

Although the pathogenesis of PSC has not been completely understood, there are some hypotheses of possible contributors such as intestinal microbiota, immunological pathways, and genetics. On the other hand, although there is no specific treatment for PSC, many studies have reported that some immunosuppressants and immunomodulatory drugs, antibiotics, and anti-inflammatory drugs can help control the disease and its complications. Studies are suggesting that controlling and normalizing levels of alkaline phosphatase in the long-term would improve survival and reduce the risk of requiring liver transplantation.


Primary Sclerosing Cholangitis Drugs

About half of patients diagnosed with PSC are asymptomatic at presentation. However, in some cases patients complain of pruritus due to extra hepatic cholestasis. It has also been shown that histamine levels are also significantly elevated in PSC patients. Several studies have attempted to examine several drugs for pruritus management such as cholestyramine, Ursodeoxycholic acid, and rifampicin. Recently, the use of melatonin has also been gaining attention in the management of gastrointestinal disease as well as anti-pruritus effect.


Primary Sclerosing Cholangitis Market Insights

Due to the rarity of the disease, studies of PSC have, until recently, been limited by small cohort size, relying on meta-analyses to improve statistical power. Display of multiple phenotypes with and without ulcerative colitis, overlapping with other autoimmune conditions, raised IgG4 and the location and the site of the biliary injury make matters worse.


Primary Sclerosing Cholangitis Market Dynamics

The dynamics of PSC market is anticipated to experience a major positive shift in the coming years owing to the expected launch of major therapies. Research is underway to identify therapeutic targets and develop a curative therapy for the treatment of primary sclerosing cholangitis (PSC).

The dynamics of primary Sclerosing cholangitis (PSC) market is anticipated to experience a positive shift in the coming years owing to the expected launch of GS-9674 (Gilead Sciences). The market is anticipated to show an extensive boost due to projected label expansion of the current therapies and emergence of potential pipeline products as approved therapies in the forecasted period (2022–2032).


Request a sample copy of the report-


Table of Content

1. Key Insights

2. Executive Summary of Primary Sclerosing Cholangitis (PSC)

3. Competitive Intelligence Analysis for Primary Sclerosing Cholangitis (PSC)

4. Primary Sclerosing Cholangitis (PSC): Market Overview at a Glance

5. Primary Sclerosing Cholangitis (PSC): Disease Background and Overview

6. Patient Journey

7. Primary Sclerosing Cholangitis (PSC) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Primary Sclerosing Cholangitis (PSC) Unmet Needs

10. Key Endpoints of Primary Sclerosing Cholangitis (PSC) Treatment

11. Primary Sclerosing Cholangitis (PSC) Marketed Products

12. Primary Sclerosing Cholangitis (PSC) Emerging Therapies

13. Primary Sclerosing Cholangitis (PSC): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Primary Sclerosing Cholangitis (PSC)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States